Key Points Company and Industry Information 1. **Company**: Bristol-Myers Squibb Company (NYSE:BMY) 2. **Event**: 43rd Annual J.P. Morgan Healthcare Conference 3. **Date**: January 13, 2024 4. **Time**: 10:30 AM ET 5. **Participants**: - Chris Boerner - Chairman and Chief Executive Officer of Bristol-Myers Squibb - Chris Schott - JPMorgan [1] Core Views and Arguments 1. **CEO's First Year**: Chris Boerner highlighted his first year as CEO, expressing pride in the company's accomplishments. 2. **Roadmap for Growth**: The company outlined a roadmap for a multi-year journey to reshape BMS with the goal of delivering sustained top-tier growth and driving long-term shareholder value. 3. **Sector Growth**: The company aims to be one of the fastest-growing companies in the sector by the end of the decade. 4. **Progress Update**: Boerner mentioned that the company is one year into this journey and closer to achieving its objectives. [4][5] Other Important Content 1. **Forward-Looking Statements**: Boerner mentioned that some of the statements made during the presentation would be forward-looking. 2. **Looking Forward**: Boerner expressed excitement about the discussions planned for the day. [5][3]

Company Overview - Bristol-Myers Squibb Company is participating in the 43rd Annual J.P. Morgan Healthcare Conference, with CEO Chris Boerner leading the presentation [1][2][3] - The company aims to reshape its operations with a focus on sustained top-tier growth and long-term shareholder value [5] Strategic Goals - The overarching goal is to become one of the fastest-growing companies in the sector by the end of the decade, with a multi-year roadmap laid out at the previous year's conference [5] - The company is one year into its journey towards achieving its growth objectives and is optimistic about its progress [5][4]

Collaboration Details - Bristol Myers Squibb has exercised its exclusive license option for ArsenalBio's AB-4000 series, a lead collaboration program under the multi-program agreement signed in December 2020 [1] - The collaboration aims to advance next-generation T cell therapies for the treatment of solid tumors [1] - ArsenalBio is responsible for discovering and building preclinical candidates against multiple targets, while Bristol Myers Squibb has the option to obtain an exclusive worldwide license to develop and commercialize these candidates [2] - Following the exercise of the option, Bristol Myers Squibb will be solely responsible for developing and commercializing the licensed candidates [2] - ArsenalBio remains eligible for additional milestone payments and royalties on potential commercial sales as the programs advance [3] ArsenalBio's Technology and Pipeline - ArsenalBio is a clinical-stage programmable cell therapy company focused on engineering advanced CAR T cell therapies for solid tumors [1] - The company leverages its proprietary synthetic biology toolkit, including CRISPR-based CITE (CRISPR Integration of Transgene via Electroporation), to create the AB-4000 series [5] - CITE cassettes include features such as PrimeR logic gates and shRNA cassettes to improve T cell product's ability to identify and eradicate solid tumors while limiting off-target effects [5] - ArsenalBio's clinical pipeline includes AB-2100 for kidney cancer and multiple preclinical candidates for prostate cancer and other solid tumors [4] - The company is pioneering an AI-enabled foundation model of the T cell using deep learning to accelerate target discovery and improve patient segmentation for drug development [4] Strategic Milestones - In January 2022, Bristol Myers Squibb exercised an option to initiate a new program, expanding its strategic collaboration with ArsenalBio [2] - In July 2023, Bristol Myers Squibb entered a limited co-exclusive commercial license agreement for the use of ArsenalBio's proprietary TME control technology to potentially increase CAR T therapeutic effects in a limited number of Bristol Myers Squibb cell therapy products [2] - The recent exercise of the exclusive license option for the AB-4000 series further strengthens the collaboration between the two companies [1]

Group 1: Company Performance - Bristol Myers Squibb (BMY) ended the recent trading session at $56.81, showing a -0.58% change from the previous day's closing price, which lagged behind the S&P 500's daily gain of 0.16% [1] - Over the past month, shares of Bristol Myers Squibb gained 0.28%, outperforming the Medical sector's loss of 5.31% and the S&P 500's loss of 2.7% [1] Group 2: Upcoming Earnings - The company's earnings report is scheduled for February 6, 2025, with analysts expecting earnings of $1.46 per share, indicating a year-over-year decline of 14.12% [2] - The Zacks Consensus Estimate for revenue projects net sales of $11.6 billion, reflecting a 1.05% increase from the year-ago period [2] Group 3: Analyst Estimates and Rankings - Recent changes to analyst estimates for Bristol Myers Squibb are important as they reflect the shifting dynamics of short-term business patterns [3] - The Zacks Rank system, which includes estimate changes, currently ranks Bristol Myers Squibb at 2 (Buy), with a 0.29% rise in the Zacks Consensus EPS estimate over the past month [5] Group 4: Valuation Metrics - Bristol Myers Squibb is trading at a Forward P/E ratio of 7.9, which is a discount compared to the industry average Forward P/E of 22.58 [6] - The company has a PEG ratio of 1.98, compared to the Medical - Biomedical and Genetics industry's average PEG ratio of 1.5 [6] Group 5: Industry Overview - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 64, placing it in the top 26% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

It was a good year for biotech giant Bristol Myers (BMY) . Shares of the company have risen 11.4% against the industry’s 15.6% decline. The stock has also outperformed the sector but underperformed the S&P 500 during this period.The outperformance was more pronounced in the second half of the year, buoyed by strong quarterly performances, an increase in annual guidance and approval of new drugs.This stupendous rally after touching a 52-week low in July has enabled BMY to regain its lost territories. The sto ...

Group 1 - The marketplace channel Haggerston BioHealth offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to investment bank-grade financial models and research [1] - The group caters to both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] - The analyst has extensive experience in the biotech sector, having covered over 1,000 companies and leading the investing group Haggerston BioHealth [3]

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tried-and-true metrics and fundamental ...

Bristol Myers Squibb (BMY) announced that the European Commission has approved the combination of its blockbuster immuno-oncology drug Opdivo (nivolumab) and Yervoy (ipilimumab) for a new cancer indication.The EC has approved Opdivo plus Yervoy for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).Following the latest nod, Opdivo plus Yervoy became the first dual checkpoint inhibitor ...

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

About five months ago, I wrote my last article about Bristol-Myers Squibb Company (NYSE: BMY ). And after being a bit more cautious in my previous article, I clearly argued that the stock was a “Buy” at this point and a bargain. InMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitaliza ...